Bluejay Diagnostics Inc (BJDX) Stock Analysis
Verdict: AVOID
Pre-revenue microcap facing ~10-month cash runway and severe historical dilution makes speculative bounce unsustainable without clinical catalyst.
Investment score: 18/100
Analysis as of
Is Bluejay Diagnostics Inc stock worth reviewing? AI model thesis
The AI model evaluates BJDX as a high-risk microcap pre-revenue diagnostic company. Despite insider purchases at $2.00 in March 2026, negative operating cash flows and impending cash depletion make the stock highly speculative.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 55/100 (weight 10%)
- Analyst Consensus: 15/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Bluejay Diagnostics Inc opportunities and risks
What speaks for BJDX
- FDA clearance or positive clinical progress for Symphony IL-6 test by Q4 2026
What speaks against BJDX
- Imminent cash exhaustion by late 2026 requiring dilutive financing
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BJDX | n/a | 0.0x | 1.2x | 0.0% | 0.0% | -568.6% |
| AMIX | n/a | 0.0x | 0.0x | 0.0% | 0.0% | -413.4% |
| RMSL | n/a | 147.0x | n/a | -0.8% | -11339589362.6% | -12845135.7% |
| FEED | n/a | 1.7x | n/a | -26.1% | -1088.9% | -368.3% |
| XAIR | n/a | 0.4x | n/a | 4.2% | -435.7% | -615.4% |
| NUWE | n/a | 0.0x | 0.5x | 69.7% | -123.4% | -13791.8% |
| Peer median | n/a | 0.4x | n/a | 0.0% | -435.7% | -615.4% |
Frequently asked questions about Bluejay Diagnostics Inc (BJDX)
Is BJDX stock a good investment?
The cached TradeMates AI model rates Bluejay Diagnostics Inc as AVOID with an investment score of 18/100. The AI model evaluates BJDX as a high-risk microcap pre-revenue diagnostic company. Despite insider purchases at $2.00 in March 2026, negative operating cash flows and impending cash depletion make the stock highly speculative. This is algorithmic model output, not personal investment advice.
Is BJDX stock a buy?
The TradeMates model verdict for BJDX is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.